Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

CVKD

Cadrenal Therapeutics Inc

Oct 17 • 04:00PM ET

16.30

Dollar change +0.95
Percentage change 6.19	%

Healthcare • Biotechnology • USA • NASD

Peers: ABBV JNJ MRK PFE LLY AMGN BMY REGN GILD VRTX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.31	Insider Own	59.15%	Shs Outstand	0.87M	Perf Week	44.63%
Market Cap	17.44M	Forward P/E	-	EPS next Y	-4.72	Insider Trans	0.00%	Shs Float	0.44M	Perf Month	36.06%
Income	-6.24M	PEG	-	EPS next Q	-1.93	Inst Own	2.19%	Short Float	4.10%	Perf Quarter	152.71%
Sales	0.00M	P/S	-	EPS this Y	17.49%	Inst Trans	-79.27%	Short Ratio	0.48	Perf Half Y	152.83%
Book/sh	3.74	P/B	4.36	EPS next Y	38.53%	ROA	-138.35%	Short Interest	0.02M	Perf Year	77.27%
Cash/sh	4.71	P/C	3.46	EPS next 5Y	-	ROE	-174.01%	52W Range	5.40 - 32.55	Perf YTD	46.87%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-156.22%	52W High	-49.92%	Beta	1.83
Dividend TTM	-	Quick Ratio	3.60	Sales past 5Y	0.00%	Gross Margin	-	52W Low	201.85%	ATR (14)	1.32
Dividend Ex-Date	-	Current Ratio	3.60	EPS Y/Y TTM	59.76%	Oper. Margin	0.00%	RSI (14)	70.84	Volatility	13.65% 11.26%
Employees	4	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	52.50
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-74.71%	Payout	-	Rel Volume	2.70	Prev Close	15.35
Sales Surprise	-	EPS Surprise	-76.47%	Sales Q/Q	-	Earnings	Aug 07 BMO	Avg Volume	37.31K	Price	16.30
SMA20	25.22%	SMA50	61.79%	SMA200	73.01%	Trades		Volume	100,656	Change	6.19%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-23	Initiated	Noble Capital Markets	Outperform	$4

Sep-23-24 04:15PM	Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference (PR Newswire) -12.17% +16.94%
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE) +17.85%
Aug-22-24 09:00AM	Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients (PR Newswire) -5.52%
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 09:00AM	Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients (PR Newswire) +19.12%
07:00AM	Loading…
07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire)
Aug-14-24 09:00AM	Cadrenal Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
Aug-12-24 05:07PM	Cadrenal Therapeutics, Inc. (CVKD): A New Penny Stock to Buy Now (Insider Monkey) +13.67%
Aug-07-24 11:53PM	CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024 (InvestorPlace)
04:05PM	Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update (PR Newswire)
Aug-06-24 09:00AM	Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs (PR Newswire)
Jul-17-24 09:00AM	Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024 (PR Newswire)
07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
04:15PM	Loading…
Jun-11-24 04:15PM	Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024 (PR Newswire) +6.34%
07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-03-24 09:00AM	Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients (PR Newswire) +5.45%
May-23-24 09:00AM	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (PR Newswire)
May-09-24 01:53PM	CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
09:00AM	Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update (PR Newswire)
Apr-11-24 04:30PM	Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 (PR Newswire) -5.34%
Apr-09-24 09:00AM	Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts (PR Newswire) -19.86%
Mar-11-24 09:00AM	Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update (PR Newswire)
Feb-26-24 09:00AM	Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference (PR Newswire)
Feb-08-24 09:00AM	Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial (PR Newswire) -19.47%
Jan-31-24 09:00AM	Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions (PR Newswire) +8.33%
Jan-24-24 09:00AM	Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 (PR Newswire) +19.25%
Jan-04-24 09:00AM	Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference (PR Newswire)
Dec-19-23 09:00AM	Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target (PR Newswire) +6.94%
09:00AM	Loading…
Dec-12-23 09:00AM	Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization (PR Newswire)
Nov-30-23 04:15PM	Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023 (PR Newswire) +8.70%
Nov-09-23 09:00AM	Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update (PR Newswire) -5.38%
Oct-16-23 08:38AM	Innovation Takes Center Stage: Florida's Life Sciences Leaders Shine at BioFlorida Conference (PR Newswire)
Oct-09-23 04:15PM	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference (PR Newswire)
Sep-05-23 08:00AM	Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress (PR Newswire)
Aug-30-23 08:00AM	Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS) (PR Newswire)
Aug-28-23 04:15PM	Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-10-23 09:00AM	Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update (PR Newswire)
Aug-01-23 09:00AM	Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases (PR Newswire)
Jul-24-23 09:00AM	Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors (PR Newswire) -11.65%
Jul-14-23 03:02PM	Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules (PR Newswire) -18.37%
Jul-12-23 03:17PM	Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules (PR Newswire) +29.31%
Jun-28-23 06:23AM	The 3 Hottest IPOs to Buy Before They Soar (InvestorPlace)
Jun-01-23 09:00AM	Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in Boston (PR Newswire)
May-10-23 09:00AM	Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update (PR Newswire)
May-09-23 04:30PM	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor Conference (PR Newswire)
Mar-30-23 09:00AM	Cadrenal Therapeutics Provides Fiscal Year 2022 Corporate Update (PR Newswire) +8.53%
Mar-09-23 09:00AM	Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient Population (PR Newswire) -7.69%
Feb-08-23 09:00AM	Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023 (PR Newswire) -9.26%
Feb-06-23 09:00AM	Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference (PR Newswire) -6.25%
Feb-01-23 09:00AM	Cadrenal Therapeutics Announces Formation of Scientific Advisory Board (PR Newswire)
Jan-24-23 02:11PM	Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering (PR Newswire) -18.37%
Jan-23-23 11:39AM	What's Going On With Cadrenal Therapeutics Stock Today (Benzinga)
08:30AM	Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation (PR Newswire)
Jan-20-23 09:31AM	Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO) (PR Newswire)

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CVKD

Cadrenal Therapeutics Inc

Upgrade your FINVIZ experience